



FINANCIAL TEAR SHEET

CORPORATE PROFILE

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

STOCK MARKET DATA

ERYP.PA (Common Stock)

Exchange	Paris (Euro)
Price	€17.26
Change (%)	▼ 0.19 (1.09%)
Volume	36,515
52 Week Low	€12.15
Market Cap	€204,896,993
Rolling EPS	-3.20
PE Ratio	0

Shares Outstanding 11,741,948

Data as of 02/19/18 3:21 p.m. ET

ERYP (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$21.51
Change (%)	▲ 0.55 (2.62%)
Volume	115
52 Week Low	\$17.50
Market Cap	\$
Rolling EPS	0.00
PE Ratio	0

Shares Outstanding

Data as of 02/16/18 3:59 p.m. ET

STOCK MARKET DATA



Data provided by Nasdaq. Minimum 15 minutes delayed.

RECENT NEWS & EVENTS

13-Feb-2018

ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase

12-Feb-2018

Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018

08-Feb-2018

ERYTECH to Present at the 2018 BIO CEO & Investor Conference

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
02/13/18	6-K
01/24/18	S-8
01/02/18	SC 13G
12/08/17	6-K

CORPORATE GOVERNANCE

Gil Beyen, MBA	Chairman and Chief Executive Officer
Eric Soyer, MBA	Chief Financial Officer & Chief Operating Officer
Yann Godfrin, PhD	Chief Scientific Officer
Iman El-Hariry, MD, PhD	Chief Medical Officer
Jérôme Bailly, Pharm.D.	Director of Pharmaceutical Operations and Qualified Person